Diamond–Blackfan Anemia Syndrome Therapeutics Market Analysis and Forecast 2023 to 2033
The global diamond-blackfan anemia (DBAAASE) syndrome therapeutics market is predicted to exceed an impressive US$ 4.8 Billion in 2023, with a compound annual growth rate (CAGR) of 4.2% from 2023 to 2033. Because 90% of infected individuals develop hematologic difficulties during their first year of life, a rise in the incidence of blood disorders catapulted the global diamond-blackfan anemia treatment market over the historical era. Moreover, growing government R&D support, changing lifestyles, and rapidly evolving technology are anticipated to propel market growth in the forecast period.
North America dominates the diamond-blackfan anaemia
syndrome therapeutics market owing to the presence of major notable
stakeholders, high expendable income, increased medical costs, and an
established medical sector in this region. According to a report published by
Clevel and Clinic, the DBA Registry of North America, a database containing
data on people who have this disorder, 25% of people with DBA die before the
age of 50 from affiliated medical disorders.
DBA UK is a registered charity (1083179) that is governed
by a written constitution and run by appointed volunteer groups. They offer
support, research, and hope to the DBA community by bringing families together
to discuss their experiences, share the most recent health history, and raise
funds to assist those with DBA in the United Kingdom.
Key Market Players
Key players in the Diamond–Blackfan
Anemia (DBA)/Aase Syndrome Therapeutics market are Sumitomo Corporation, Johnson &
Johnson Private Limited, Novartis AG, Pfizer Inc, Sanofi, Merck KGaA, LEO
Pharma A/S, Cipla Inc., GlaxoSmithKline plc, AstraZeneca, Abbott, Bayer AG.
More Valuable
Insights Available
Future Market Insights
offers an unbiased analysis of the global diamond-blackfan anemia (DBAAASE)
syndrome therapeutics market, providing historical data for 2018 to 2022 and
forecast statistics from 2023 to 2033.
Know
More About Report@ https://www.futuremarketinsights.com/reports/diamond-blackfan-anemia-syndrome-therapeutics-market
Key
Segments Profiled in the Diamond–Blackfan Anemia (DBAAASE) Syndrome
Therapeutics Market Industry Survey
By
Treatment:
- Corticosteroids
- Chelation
Therapy
- Blood
Transfusions
- Stem
Cell Transplant
- Others
By End
User:
- Hospitals
- Clinics
- Others
Comments
Post a Comment